STUDY AIMS: VEXAS syndrome is a recently discovered monogenic auto-inflammatory disease caused by a somatic mutation in the UBA1 gene that manifests with rheumatologic and haematologic features. In this report, we present the first Swiss cohort, detailing its manifestations and treatment outcomes among Swiss patients.
METHODS: Data were retrospectively collected from nine hospitals across Switzerland, representing a broad geographic distribution. Treating physicians completed a standardised case report form for each patient. The principal investigator and the co-investigators collected and analysed all case report forms.
RESULTS: We identified 23 patients between July 2022 and 2023, of which 17 are described. All were male. They presented with skin manifestations (88%), general symptoms (82%), venous thromboembolism (59%), ocular manifestation (59%), lung infiltrates (59%) and articular manifestations (47%). Central nervous system and kidney manifestations were very rare, and heart and digestive manifestations were absent. Macrocytic anaemia was present in all patients throughout the disease progression but only in two-thirds of patients (12/17, 71%) at the time of diagnosis. Clinical response was reached in all cases treated with ruxolitinib (4/4, 100%), upadacitinib (1/1, 100%), azacytidine (5/5, 100%) and haematopoietic stem cell transplantation (2/2, 100%). All deaths were attributed to infections (5/5, 100%).
CONCLUSION: This study corroborates the clinical spectrum of VEXAS syndrome described in other cohorts. It suggests that VEXAS syndrome is not limited to patients with macrocytic anaemia. In this study, azacytidine has been used effectively among patients with myelodysplastic syndrome. In addition, Janus kinase (JAK) inhibitors, particularly ruxolitinib, have been successfully used even in those without myelodysplastic syndrome. We report two successful treatments by haematopoietic stem cell transplantation.
References
Jachiet V, Ricard L, Hirsch P, Malard F, Pascal L, Beyne-Rauzy O, et al.; MINHEMON: French Network of dysimmune disorders associated with hemopathies. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases. Clin Exp Med. 2023 Jul;23(3):803–13. doi: https://doi.org/10.1007/s10238-022-00866-5
Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020 Dec;383(27):2628–38. doi: https://doi.org/10.1056/NEJMoa2026834
Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al.; French VEXAS group; GFEV, GFM, CEREMAIA, MINHEMON. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022 Mar;186(3):564–74. doi: https://doi.org/10.1111/bjd.20805
Boyadzhieva Z, Ruffer N, Kötter I, Krusche M. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology (Oxford). 2023 Nov;62(11):3518–25. 10.1093/rheumatology/kead240
Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2022 Feb;6(3):998–1003. 10.1182/bloodadvances.2021004749
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct;370(9596):1453–7. doi: https://doi.org/10.1016/S0140-6736(07)61602-X
van der Made CI, Potjewijd J, Hoogstins A, Willems HP, Kwakernaak AJ, de Sevaux RG, et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS. J Allergy Clin Immunol. 2022 Jan;149(1):432–439.e4. doi: https://doi.org/10.1016/j.jaci.2021.05.014
Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. JAMA. 2023 Jan;329(4):318–24. doi: https://doi.org/10.1001/jama.2022.24836
Stubbins RJ, McGinnis E, Johal B, Chen LY, Wilson L, Cardona DO, et al. VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome). Haematologica. 2022 Apr;107(4):1011–3. doi: https://doi.org/10.3324/haematol.2021.280238
Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H, Gutierrez-Rodrigues F, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022 Sep;140(13):1496–506. doi: https://doi.org/10.1182/blood.2022016985
Beecher MB, Tong JY, Halliday LA, Hissaria P, Selva D. Recurrent orbital inflammation associated with VEXAS syndrome. Orbit. 2022;0(0):1–4.
Vitale A, Caggiano V, Martin-Nares E, Frassi M, Dagna L, Hissaria P, et al. Orbital/ocular inflammatory involvement in VEXAS syndrome: data from the international AIDA network VEXAS registry. Semin Arthritis Rheum. 2024 Jun;66:152430. 10.1016/j.semarthrit.2024.152430
Sota J, Vitale A, Fabiani C, Frediani B, Rigante D, Tosi GM, et al. The eye involvement in monogenic autoinflammatory diseases: literature review and update. Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):44-53.
Sfiniadaki E, Tsiara I, Theodossiadis P, Chatziralli I. Ocular Manifestations of Granulomatosis with Polyangiitis: A Review of the Literature. Ophthalmol Ther. 2019 Jun;8(2):227–34. doi: https://doi.org/10.1007/s40123-019-0176-8
Khitri MY, Guedon AF, Georgin-Lavialle S, Terrier B, Saadoun D, Seguier J, et al.; French VEXAS group and MINHEMON. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open. 2022 Jul;8(2):e002255. doi: https://doi.org/10.1136/rmdopen-2022-002255
Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM, et al. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis Rheumatol. 2021 Oct;73(10):1886–95. doi: https://doi.org/10.1002/art.41743
Borie R, Debray MP, Guedon AF, Mekinian A, Terriou L, Lacombe V, et al.; French VEXAS Group. Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome. Chest. 2023 Mar;163(3):575–85. doi: https://doi.org/10.1016/j.chest.2022.10.011
Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Enaka M, Yamaguchi Y, et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. 2021 Aug;80(8):1057–61. doi: https://doi.org/10.1136/annrheumdis-2021-220089
Akdoğan Ö, Exilus S, Ward BK, McArthur JC, Della Santina CC, Carey JP. Sudden Sensorineural Hearing and Vestibular Loss in a Case of Relapsing Polychondritis. Ann Otol Rhinol Laryngol. 2021 Dec;130(12):1412–6. doi: https://doi.org/10.1177/00034894211005979
Muratore F, Marvisi C, Castrignanò P, Nicoli D, Farnetti E, Bonanno O, et al. VEXAS syndrome: a case series from a single-center cohort of Italian patients with vasculitis. Arthritis Rheumatol. 2021; n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41992
Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK, et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv. 2021 Aug;5(16):3203–15. doi: https://doi.org/10.1182/bloodadvances.2021004976
Gutierrez-Rodrigues F, Kusne Y, Fernandez J, Lasho T, Shalhoub R, Ma X, et al. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood. 2023 Jul;142(3):244–59. doi: https://doi.org/10.1182/blood.2022018774
Battipaglia G, Vincenzi A, Falconi G, Fiore A, D’Agostino F, Iannotta R, et al. New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: evolution from myelodysplastic syndrome to acute myeloid leukemia. Curr Res Transl Med. 2023;71(2):103386. doi: https://doi.org/10.1016/j.retram.2023.103386
Terrier B, Posseme C, Temple M, Corneau A, Carbone F, Chenevier-Gobeaux C, et al. Le syndrome VEXAS se caractérise par une activation des voies de l’inflammasome dans le sang et les tissus et par une dérégulation du compartiment monocytaire. Rev Med Interne. 2022 Dec;43:A384. 10.1016/j.revmed.2022.10.097
Staels F, Betrains A, Woei-A-Jin FJ, Boeckx N, Beckers M, Bervoets A, et al. Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome. Front Immunol. 2021 Apr;12:678927. doi: https://doi.org/10.3389/fimmu.2021.678927
Yoon JG, Lee S, Kim S, Kim MJ, Chang YH, Park JK, et al. The First Korean Case of VEXAS Syndrome Caused by a UBA1 Somatic Variant. Ann Lab Med. 2023 Mar;43(2):217–20. doi: https://doi.org/10.3343/alm.2023.43.2.217
Heiblig M, Ferrada MA, Gerfaud-Valentin M, Barba T, Mékinian A, Koster M, et al. Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study. Blood. 2021 Nov;138 Supplement 1:2608. doi: https://doi.org/10.1182/blood-2021-150394
Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022 Aug;140(8):927–31. doi: https://doi.org/10.1182/blood.2022016642
Comont T, Heiblig M, Rivière E, Terriou L, Rossignol J, Bouscary D, et al.; French VEXAS study group, Groupe Francophone des Myélodysplasies (GFM) and MedecineINterne, HEmato et ONco (MINHEMON) group. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol. 2022 Feb;196(4):969–74. doi: https://doi.org/10.1111/bjh.17893
Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC, et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. 2021 Jul;137(26):3682–4. doi: https://doi.org/10.1182/blood.2020010177
Campochiaro C, Tomelleri A, Cavalli G, De Luca G, Grassini G, Cangi MG, et al. Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series. Arthritis Rheumatol. 2022 Jul;74(7):1302–3. doi: https://doi.org/10.1002/art.42101